Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com11-05

Total Revenue: $175.7 million for Q3 2024, up from $153.9 million in Q3 2023. Net Product Sales: $170.3 million for Q3 2024. Operating Earnings (GAAP): $40.9 million for Q3 2024, up from $8.1 million ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481504268?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cFz6WvyfjpF8EORFfE5g6A--~B/aD0zMDg7dz0zMDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/318705bd1b46f1b2974b2b539d866bc2","is_english":true,"pubTime":"2024-11-05 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481504268","market":"us","top_or_hot":-1,"title":"Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...","media":"GuruFocus.com","content":"<div>\n<p>Total Revenue: $175.7 million for Q3 2024, up from $153.9 million in Q3 2023.\nNet Product Sales: $170.3 million for Q3 2024.\nOperating Earnings (GAAP): $40.9 million for Q3 2024, up from $8.1 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/supernus-pharmaceuticals-inc-supn-q3-130031886.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/supernus-pharmaceuticals-inc-supn-q3-130031886.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Revenue: $175.7 million for Q3 2024, up from $153.9 million in Q3 2023.\nNet Product Sales: $170.3 million for Q3 2024.\nOperating Earnings (GAAP): $40.9 million for Q3 2024, up from $8.1 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/supernus-pharmaceuticals-inc-supn-q3-130031886.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"https://finance.yahoo.com/news/supernus-pharmaceuticals-inc-supn-q3-130031886.html","article_id":"2481504268","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cFz6WvyfjpF8EORFfE5g6A--~B/aD0zMDg7dz0zMDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/318705bd1b46f1b2974b2b539d866bc2"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481504268","pubTimestamp":1730811631,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Total Revenue: $175.7 million for Q3 2024, up from $153.9 million in Q3 2023.Net Product Sales: $170.3 million for Q3 2024.Operating Earnings : $40.9 million for Q3 2024, up from $8.1 million in Q3 2023.Net Earnings : $38.5 million for Q3 2024, or $0.69 per diluted share, compared to a net loss of $16 million in Q3 2023.Adjusted Operating Earnings : $67.7 million for Q3 2024, up from $37.3 million in Q3 2023.Cash and Marketable Securities: $403.2 million as of September 30, 2024.Revenue Guidance for 2024: Raised to $630 million to $650 million.R&D and SG&A Expenses: $98.8 million for Q3 2024, down from $105.4 million in Q3 2023.Prescription Growth: KVIS prescriptions grew 19% with net sales up 68% in Q3 2024.GuruFocus has detected 9 Warning Signs with SUPN.Supernus Pharmaceuticals Inc  reported a 26% increase in total revenues for the third quarter of 2024, driven by strong performance from key growth products.Supernus Pharmaceuticals Inc  raised its financial guidance for the full yea","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals"},"translate_title":"Supernus Pharmaceuticals Inc(SUPN)2024年第三季度收益看涨期权亮点：强劲的收入增长和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1},"content_text":"Total Revenue: $175.7 million for Q3 2024, up from $153.9 million in Q3 2023.\nNet Product Sales: $170.3 million for Q3 2024.\nOperating Earnings (GAAP): $40.9 million for Q3 2024, up from $8.1 million in Q3 2023.\nNet Earnings (GAAP): $38.5 million for Q3 2024, or $0.69 per diluted share, compared to a net loss of $16 million in Q3 2023.\nAdjusted Operating Earnings (Non-GAAP): $67.7 million for Q3 2024, up from $37.3 million in Q3 2023.\nCash and Marketable Securities: $403.2 million as of September 30, 2024.\nRevenue Guidance for 2024: Raised to $630 million to $650 million.\nR&D and SG&A Expenses: $98.8 million for Q3 2024, down from $105.4 million in Q3 2023.\nPrescription Growth: KVIS prescriptions grew 19% with net sales up 68% in Q3 2024.\nNet Sales of Key Products: KVIS net sales were $62 million; Recovery net sales were $36 million, up 8% from Q3 2023.\n\n\nWarning! GuruFocus has detected 9 Warning Signs with SUPN.\n\nRelease Date: November 04, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nSupernus Pharmaceuticals Inc (NASDAQ:SUPN) reported a 26% increase in total revenues for the third quarter of 2024, driven by strong performance from key growth products.\nThe company achieved a significant 68% growth in net sales for its product KVIS, with prescriptions reaching an all-time quarterly high.\nSupernus Pharmaceuticals Inc (NASDAQ:SUPN) raised its financial guidance for the full year 2024, expecting total revenues to range from $630 million to $650 million.\nThe company reported a substantial increase in operating earnings, with a $32.8 million rise compared to the same quarter last year.\nSupernus Pharmaceuticals Inc (NASDAQ:SUPN) has a strong balance sheet with approximately $403.2 million in cash and no debt, providing financial flexibility for potential M&A opportunities.\n\n Negative Points \n\nNet sales for legacy products like Trendi Xr and Oxtellar Xr showed declines, with Trendi Xr down 26% from the same quarter last year.\nThe first generic for Elex R entered the market, resulting in a 26% sequential decline in monthly prescriptions, indicating potential future erosion.\nThe company expects further erosion in Trendi Xr sales for the remainder of 2024 and into 2025.\nSupernus Pharmaceuticals Inc (NASDAQ:SUPN) faces potential competition from new non-stimulant entrants in the ADHD market, which could impact future sales.\nThe company's pipeline products are still in early stages, with SPN 817 and SPN 820 in phase two trials, indicating a longer timeline before potential market entry.\n\n Q & A Highlights \nQ: Are we interpreting the new data correctly that the overall seizure reduction for patients at 3 to 4 mg doses through the maintenance period is now 56% on 10 total patients? A: Yes, the seizure reduction is 56% in the maintenance period for 10 subjects on 3 mg and 4 mg doses. In the post-maintenance extension period, the reduction increased to 66%. This exploratory study shows promising results, and we are focusing on the main patient population with focal seizures and the doses of 3 to 4 mg for further studies.\nQ: Regarding the apomorphine pump under review, how might the recent approval of a similar pump affect your review process? A: We are excited about the potential approval of our pump in February. The presence of another company in the market will help educate patients about this treatment segment. We believe there is enough room for both products, as many patients could benefit from these options before resorting to invasive treatments.\nQ: Do you expect the drug effect seen in the recent MDD study to be replicated in the TRD study with data in the first half of next year? A: It's hard to predict, but the open-label study showed promising results with significant reductions in depression symptoms. We hope these results will be replicated in the placebo-controlled TRD study. The remission and response rates observed in the open-label study are encouraging.\nQ: How are you thinking about the current volumes for Calvary and the trajectory for 2025? A: We are pleased with the growth of Calvary, with a 25% increase in prescriptions year-to-date. The increase in 90-day prescriptions indicates strong retention and compliance. We expect this growth to continue into 2025, and we will provide more specifics in February.\nQ: What are your latest thoughts on capital deployment and M&A, particularly regarding commercial stage assets versus pipeline-focused assets? A: Our priority remains on acquiring commercial products that provide revenue growth and cash flow. We are also interested in pipeline assets at a later stage than our own. We focus on CNS but are open to other specialty areas if they offer a strong presence and growth potential.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481504268"}